InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,277.51
(
0.80%
)
US TECH 100
18,028.40
(
0.00%
)
Dow Jones
38,686.32
(
1.51%
)
Brent Oil
81.12
(
0.38%
)
Bitcoin
68,841.59
(
1.62%
)
Post# of 252012
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 830
Posts 119742
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 237898

Monday, 12/18/2023 7:38:21 PM

Monday, December 18, 2023 7:38:21 PM

Post# of 252012
CARA—(-49%)—flops again in pruritis/AD—discontinues program:

https://finance.yahoo.com/news/cara-therapeutics-announces-outcome-dose-120000127.html

Oral difelikefalin as adjunct to topical corticosteroids (TCS) did not demonstrate meaningful clinical benefit compared to TCS alone; As a result, Cara will discontinue its clinical program in pruritus associated with atopic dermatitis

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up